N/A N=530 FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging
Fever
Primary: Fever >= 100.4 — 7.5; 37.6; 9.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=221 Fever After Simultaneous Versus Sequential Vaccination in Young Children
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
Phase 4 N=908 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
Pneumococcal Vaccines
Primary: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series — 1.64; 1.99; 1.48; 2.07 microgram…
Phase 3 N=2,133 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. — 56…
Phase 4 N=60 Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever
Fever
Primary: Child Temperature (Degrees C)Over 6 Hours — 38.5; 37.2; 36.9 degrees Celcius — p=<0.001
Phase 3 N=374 Acetaminophen Before Vaccines for Infants Study (AVIS)
Fever
Primary: Fever >=38C Within 32 Hours of Vaccination. — 14; 22 percentage of participants — p=0.053
Phase 4 N=812 Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
Infections, Streptococcal
Primary: Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes Greater Than or Equal to (≥) the Cut-off — 144; 155; 160; 52 Participants
Phase 4 N=1,950 Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Influenza
Primary: Percentage of Participants With Fever (Fever Rate) Following Vaccination With Fluzone Quadrivalent Vaccine — 11.31; 12.15 percentage of participants
Phase 3 N=750 Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A
Infections, Streptococcal
Primary: Number of Subjects Reported With Core Fever (Rectal Temperature) Greater Than or Equal to (≥) the Cut-off — 64; 14; 100; 16 Participants
Phase 2 N=256 Aggressive Antipyretics for Fever Reduction in CNS Malaria
Malaria · Seizures · Coma
Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001
N/A N=20 Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
Phase 2 N=56 Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
Phase 4 N=41 Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults
Fever · Critical Illness
Primary: Core Body Temperature — 38.4; 37.9 degrees Celsius — p=0.002
N/A N=273 Video Discharge Instructions for Fever and ED Recidivism
Children Who Present to the ED With Minor Febrile Illnesses
Primary: Recidivism — 6; 3 number of return visits within 72 ho
Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
Phase 4 N=347 Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
Fever After Vaccination · Fever · Seizures Fever
Primary: Number of Participants With Fever Following Vaccination — 14; 10 Participants
Phase 3 N=105 Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males
Fever
Primary: The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2) — 0.3; 0.6 Degrees Celsius
Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants
Phase 3 N=1,437 Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
Hepatitis B · Acellular Pertussis · Tetanus
Primary: Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C) — 11; 8 subjects
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 4 N=33 Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
Influenza
Primary: Number of Participants Reporting Solicited Local and Systemic Reactions After Fluzone® Vaccination — 9; 6; 0; 2 Participants
N/A N=108 Hospital Admissions in Children Aged 3 Months to 5 Years Presenting With Fever to the Emergency Department
Fever
Primary: Number of Participants With Admission to Hospital Due to Parental High Levels of Worry — 87 Participants
N/A N=3,493 Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
N/A N=100 Prevenar (PCV-7) Post-Licensure Safety Study In Russia
Healthy Children After Vaccination
Primary: Percentage of Participants With Febrile Reactions Post-dose 1 — 14.3; 16.1; 1.8; 0.0 Percentage of participants
Phase 2 N=82 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Comparison of Anti-YF Antibody Levels by Measurement of Log10 Neutralization Index (LNI): YFV-17D TC- (AD) Participants Compared to YFV-17D TC- (Non-AD) Participants…
Phase 3 N=1,630 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Meningococcal Infections
Primary: Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine — 98…
Phase 2 N=47 Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury
Subarachnoid Hemorrhage · Subdural Hematoma · Traumatic Brain Injury
Primary: Temperature Burden — 37.8; 37.7 Temperature in degrees Celsius
N/A N=166 PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging
Pregnancy
Primary: Number of Recruited Eligible Pregnant Women <20 Weeks Gestational Age — 166 Participants
Phase 3 N=1,503 Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects
Influenza
Primary: Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects — 329.76; 334.98; 334.98; 401.21 titers
Phase 2 N=257 Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination
Infections, Streptococcal
Primary: Number of Subjects With Fever > 40.0°C (Rectal Temperature) — 0; 1 Participants